Our Mission

AIRA's mission is to build the decision infrastructure for modern clinical development, empowering teams to navigate complexity with rigor and confidence.

Join our team
Founder Story

Built from personal experience of what it means when the right treatment isn't available

AIRA Health co-founders — Milan Nguyen (AI Lead), Levente Fazekas (CEO), George Buslig (CPO)
AIRA co-founders — Milan, Levi & George.

AIRA was founded by a team of curious minds working at the intersection of clinical development, technology, econometrics, and mathematics - united by a shared experience: the understanding that it is critical for treatments to reach patients at the right time.

Our CEO, Levi, experienced this reality firsthand during his years as a competitive athlete, when effective treatment options were not available when he needed them most. That experience ultimately brought him to Boston, where he studied at Harvard and worked at Mass General Brigham. While collaborating closely with some of the world's leading researchers and clinicians, a broader challenge became clear: the journey from scientific discovery to approved therapy is long, complex, and too often slowed not by science itself, but by fragmented processes and increasingly complex decision-making.

Early on, one insight stood out. Clinical development is fundamentally an exercise in alignment - bringing together science, safety, regulatory expectations, operational execution, and human judgment across many stakeholders. Yet the systems supporting this process were prone to misalignment, repeated work, and costly delays. The solution was not simply automating inefficient workflows, but rethinking how clinical development itself should operate - making it safer, faster, and more coherent from the ground up.

While many AI solutions focused on faster text generation or isolated automation, the AIRA team took a different path. We brought together clinicians, mathematicians, engineers, and world-class industry advisors to build something deeper: a unified platform with an intelligence layer designed to support how clinical decisions are actually made and how AI can support teams to make better, defensible decisions. Our ambition was not incremental efficiency but a structural shift toward a new, regulatory-grade approach to developing therapies with AI.

Today, AIRA is built to address the underlying complexity of clinical development and help establish a new standard for how studies are designed - ensuring that the right treatments reach patients faster and more safely. Because every failed study delays a cure.

AIRA now supports a growing community of leading clinical development teams and experts around the world as they design the next generation of therapies.

The Team

The people behind AIRA

A multidisciplinary team combining clinical expertise and AI engineering. Hover over a card to hear why AIRA's mission matters to each of us.

Levi

Levi

"

Clinical development is too slow and fragmented. AIRA exists to give every team the intelligence they need to move faster - and get therapies to patients sooner.

George

George

"

I see clinical trial design as the sweet spot for AI like AIRA to help humanity, enabling experts to make sense of vast amounts of unstructured data in a flexible and infinitely scalable way so cures can reach the market faster than ever.

Milan

Milan

"

What excites me about AIRA is encoding the complexity of clinical trial design into intelligent systems that can help researchers make better decisions and ultimately bring treatments to patients faster.

Marton

Marton

"

What matters most to me is accelerating clinical trials through technology that can bring life-saving treatments to patients even a few months earlier.

David

David

"

I aim to turn the friction of clinical development into a launchpad, using AI to shorten the distance between a discovery in the lab and a cure reaching patients worldwide.

Hansel, MD

Hansel, MD

"

As a clinician, I've seen firsthand how much critical knowledge gets lost in the chaos of a trial. AIRA changes that.

Angel

Angel

"

I see AIRA as a place where creativity and problem-solving come together to transform clinical development and play an increasingly important role in shaping its future.

MC

Marci

"

I focus on building product features that make complex work simpler and tools people genuinely want to use.

Moon

Moon

"

I see AIRA streamlining the most expensive stage of drug development, allowing companies to reinvest those savings into expanding their pipelines and reaching more patients.

Dora

Dora

"

What excites me about AIRA is the people — clinicians, engineers, and AI experts working together to solve real problems so teams can focus on what truly matters: making lives better.

Zahra, PhD

Zahra, PhD

"

At AIRA, I believe that when data, science, and innovation come together, we can design better trials and accelerate life-changing therapies for patients.

Ahmed, PhD

Ahmed, PhD

"

I'm excited about AIRA because it can make the path from clinical insight to patient impact more efficient and more reliable.

A

Adam

"

I see enormous potential in large language models for science, and at AIRA I focus on making them truly useful for clinical teams.

G

Gina

"

At AIRA, I focus on creating the internal foundation that allows the team to do its best work and drive real impact in clinical development.

Laszlo

Laszlo

"

I focus on building practical, reliable tools for clinical teams. The goal is to help investigators work better, not just follow trends.

Levi

Levi

"

Clinical development is too slow and fragmented. AIRA exists to give every team the intelligence they need to move faster - and get therapies to patients sooner.

George

George

"

I see clinical trial design as the sweet spot for AI like AIRA to help humanity, enabling experts to make sense of vast amounts of unstructured data in a flexible and infinitely scalable way so cures can reach the market faster than ever.

Milan

Milan

"

What excites me about AIRA is encoding the complexity of clinical trial design into intelligent systems that can help researchers make better decisions and ultimately bring treatments to patients faster.

Marton

Marton

"

What matters most to me is accelerating clinical trials through technology that can bring life-saving treatments to patients even a few months earlier.

David

David

"

I aim to turn the friction of clinical development into a launchpad, using AI to shorten the distance between a discovery in the lab and a cure reaching patients worldwide.

Hansel, MD

Hansel, MD

"

As a clinician, I've seen firsthand how much critical knowledge gets lost in the chaos of a trial. AIRA changes that.

Angel

Angel

"

I see AIRA as a place where creativity and problem-solving come together to transform clinical development and play an increasingly important role in shaping its future.

MC

Marci

"

I focus on building product features that make complex work simpler and tools people genuinely want to use.

Moon

Moon

"

I see AIRA streamlining the most expensive stage of drug development, allowing companies to reinvest those savings into expanding their pipelines and reaching more patients.

Dora

Dora

"

What excites me about AIRA is the people — clinicians, engineers, and AI experts working together to solve real problems so teams can focus on what truly matters: making lives better.

Zahra, PhD

Zahra, PhD

"

At AIRA, I believe that when data, science, and innovation come together, we can design better trials and accelerate life-changing therapies for patients.

Ahmed, PhD

Ahmed, PhD

"

I'm excited about AIRA because it can make the path from clinical insight to patient impact more efficient and more reliable.

A

Adam

"

I see enormous potential in large language models for science, and at AIRA I focus on making them truly useful for clinical teams.

G

Gina

"

At AIRA, I focus on creating the internal foundation that allows the team to do its best work and drive real impact in clinical development.

Laszlo

Laszlo

"

I focus on building practical, reliable tools for clinical teams. The goal is to help investigators work better, not just follow trends.

Join our team

Boston · Budapest · Barcelona

Scientific & Regulatory Advisory Board

Scientific Advisors

Pasi A. Jänne, MD, PhD

Pasi A. Jänne, MD, PhD

Professor of Medicine, Harvard Medical School

Senior Vice President for Translational Medicine, Dana-Farber Cancer Institute

Stephen T.C. Wong, PhD

Stephen T.C. Wong, PhD

Chief Research Information Officer, Houston Methodist Cancer Center

Presidential Distinguished Chair in Biomedical Engineering

David Harrington, PhD

David Harrington, PhD

Professor Emeritus of Biostatistics, Harvard T.H. Chan School of Public Health

Former Lead Statistical Editor, NEJM

Hiroto Hatabu, MD, PhD

Hiroto Hatabu, MD, PhD

Professor of Radiology, University of Pennsylvania

Emeritus Professor, Brigham and Women's Hospital

Yi Li, PhD

Yi Li, PhD

Professor of Biostatistics, University of Michigan

Elected Fellow, American Statistical Association

We value your privacy

We use cookies to improve your browsing experience and analyze site traffic. By accepting, you help us make AIRA better for everyone. Cookie Policy